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COX-1 = cyclooxygenase-1; COX-2 = cyclooxygenase-2; MI = myocardial infarction; NSAID = nonsteroidal anti-inflammatory agent; PGI2 = prosta-
cyclin; TXA2 = thromboxane A2.
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Introduction
Aspirin and traditional nonsteroidal anti-inflammatory
agents (NSAIDs) are effective analgesic and anti-inflam-
matory agents, but they also have significant gastrointesti-
nal toxicity. The gastrointestinal toxicity of NSAIDs is
apparently related to inhibition of the cyclooxygenase-1
(COX-1) isoform [1]. Following the discovery by Fu et al.
of a novel COX protein in monocytes stimulated by inter-
leukin [2], Kujubu et al. identified a gene with significant
homology to COX-1 [3]. Identification of this cyclooxyge-
nase-2 (COX-2) isoform resulted in the development of
selective COX-2 inhibitors, with the hope of producing a
safer analgesic and anti-inflammatory agent. The COX-2
inhibitors have generated rapid growth in the US anti-
arthritic market, with total sales exceeding $4.7 billion in
2001 and a 28% growth in year over year sales [4].
The hypothesis of the safety of COX-2 inhibitors as anti-
inflammatory agents is based on the premise that COX-1
predominates in the stomach, yielding protective
prostaglandins, while COX-2 is induced in inflammation
giving rise to pain, swelling and discomfort. It has now
been unequivocally demonstrated, however, that selective
COX-2 inhibitors also decrease vascular prostacyclin
(PGI2) production and may affect the homeostatic balance,
leading to a prothrombotic state [5]. By decreasing
vasodilatory and antiplatelet aggregatory PGI2 production,
COX-2 inhibitors may tip the balance in favor of prothrom-
botic eicosanoids (thromboxane A2 [TXA2]) and may lead
to increased cardiovascular thrombotic events [6].
Preclinical/molecular studies
Several basic research studies have demonstrated benefi-
cial cardiac effects of the COX-2 enzyme and potential
harmful effects of COX-2 inhibitors. Shinmura et al.
demonstrated that COX-2 mediates the cardioprotective
effects of the late phase of ischemic preconditioning [7].
By examining the late phase of ischemic preconditioning
in rabbits, they demonstrated that ischemic precondition-
ing resulted in a rapid increase in myocardial COX-2
mRNA levels. This was followed by an increase in COX-2
protein expression and in the myocardial content of
prostaglandin E2 and 6-keto-PGF(1α) [7]. Administration
of two unrelated COX-2 selective inhibitors (NS-398 and
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celecoxib) 24 hours after ischemic preconditioning abol-
ished the ischemic preconditioning-induced increase in
tissue levels of prostaglandin E2 and 6-keto-PGF(1α). The
same doses of NS-398 and celecoxib, given 24 hours
after ischemic preconditioning, completely blocked the
cardioprotective effects of late preconditioning against
both myocardial stunning and myocardial infarction (MI),
indicating that COX-2 activity is necessary for ischemic
preconditioning to occur. These results demonstrate that
upregulation of COX-2 plays an essential role in the car-
dioprotection afforded by the late phase of ischemic pre-
conditioning [7].
Hennan et al. demonstrated the important role of COX-2
in the homeostatic balance by showing that the increase in
time to vascular occlusion with aspirin in a canine coro-
nary thrombosis model was abolished with a selective
COX-2 inhibitor, celecoxib [8]. In their study of canine cir-
cumflex coronary artery thrombosis, oral high-dose aspirin
produced a significant increase in time to arterial occlu-
sion. This observed increase in time to occlusion was
abolished when celecoxib was coadministered to animals
dosed with aspirin. The study of Hennan et al. also sug-
gests the important role of COX-2-derived PGI2, and it
raises concerns regarding an increased risk of acute vas-
cular thrombotic events in patients receiving COX-2
inhibitors [8].
Other beneficial effects of COX-2 have also been demon-
strated in the heart. Dowd et al. demonstrated that inhibi-
tion of COX-2 aggravates doxorubicin-mediated cardiac
injury in vivo [9]. Doxorubicin induces COX-2 activity in rat
neonatal cardiomyocytes, and this expression of COX-2
limits doxorubicin-induced cardiac cell injury. Doxorubicin-
increased cardiac injury was aggravated by coadministra-
tion of SC236 (a COX-2 inhibitor) but not of SC560 (a
COX-1 inhibitor).
Cheng  et al. [10] recently used an elegant transgenic
knockout mice model to further elucidate the important
physiological role of COX-2 enzyme in vascular homeosta-
sis. The investigators studied deletions of the
prostaglandin receptor to understand the effects of
COX-2 inhibitors in vivo. Mice with an absent
prostaglandin receptor (IPKO) should mimic the clinical
effect of taking COX-2 agents, as these drugs would
inhibit prostaglandin production without affecting TXA2.
The COX-2 knockout resulted in an enhanced proliferative
response to injury and in a significant increase in TXA2
biosynthesis. These results suggest that PGI2 may modu-
late the platelet–vascular interactions in vivo, and that
PGI2 may have a beneficial effect by specifically limiting
the prothrombotic response to TXA2. These well-
designed, in vivo gene knockout studies raise further sig-
nificant concern about the prothrombotic effects and
cardiovascular safety of COX-2 inhibitors.
Clinical studies
Notably, clinical data with COX-2 inhibitors have also
raised concerns about cardiovascular safety [11]. There
have been two major multicenter trials with these agents,
and several smaller studies.
The Vioxx Gastrointestinal Outcomes Research Study trial,
a double-blind, randomized, stratified, parallel group study
of 8076 patients, compared the gastrointestinal toxicity of
50 mg rofecoxib daily or 1000 mg naproxen daily during
chronic treatment for patients with rheumatoid arthritis
[12]. Aspirin use was not permitted in the study. The
results of the event-free survival analysis showed that the
relative risk of developing a cardiovascular event in the
rofecoxib treatment arm was 2.37 (95% confidence inter-
val = 1.39–4.06, P = 0.0016) [13].
The Celecoxib Arthritis Safety Study was a double-blind,
randomized, controlled trial of 8059 patients. These par-
ticipants were randomized to receive either 400 mg cele-
coxib twice per day, 800 mg ibuprofen three times per day
or 75 mg diclofenac twice per day [14]. Aspirin use
(<325 mg/day) was permitted in this study. The Celecoxib
Arthritis Safety Study trial with celecoxib demonstrated no
statistically significant difference in cardiovascular events
as compared with the NSAIDs. However, there was a
numerical excess of MI events in the celecoxib group,
regardless of whether patients were concurrently taking
aspirin. Since the trial was not powered to detect an
increase in MI, one cannot conclude that celecoxib is
exempt from prothrombotic events, especially with the
trend for more MIs.
A combined analysis of 23 phase IIb–phase V rofecoxib
studies demonstrated no evidence for an excess of cardio-
vascular events for rofecoxib relative to either placebo or
the non-naproxen NSAIDs that were studied [15].
Konstam  et al., employees of the manufacturer of rofe-
coxib, concluded that differences observed between rofe-
coxib and naproxen were the result of the antiplatelet
effects of naproxen. A large cohort study by Ray et al.
[16], however, demonstrated that there was no protective
effect of naproxen on the risk of coronary heart disease
(rate ratio = 0.95, 95% confidence interval = 0.82–1.09).
Other major limitations of the analysis by Konstam et al.
[15] include combining heterogeneous patient popula-
tions receiving different dosages of the COX-2 agents.
Not a single study has considered patients with coronary
heart disease or was designed to assess cardiovascular
safety.
A second-generation, even more selective COX-2 agent,
etoricoxib, has more recently been tested in two trials
[17,18]. Although identical in design and drug dosages,
and very similar in size, the trials reported discordant find-
ings. The study by Collantes et al. [18] demonstrated no10
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difference in efficacy between etoricoxib and naproxen in
treating patients with rheumatoid arthritis, while the study
by Matsumoto et al. demonstrated etoricoxib to be signifi-
cantly more effective [17]. More importantly, despite
excluding patients with a history of cardiovascular disease
in the form of angina, congestive heart failure, history of
MI, coronary angioplasty, coronary bypass, stroke and
transient ischemic attacks, there were two adjudicated
cardiovascular events out of 323 patients in the
Matsumoto et al. study [17], and two events out of 353
patients in the study by Collantes et al. [18]. A recent
analysis by Ray et al. of individuals on the Tennessee Med-
icaid Program demonstrated that users of high dose rofe-
coxib were 1.70 (95% confidence interval 0.98–2.95,
P = 0.058) times more likely than non users to have coro-
nary artery disease [19].
Conclusions
Seminal experimental studies, including those with knock-
out mice, have demonstrated that the COX-2 isoform pro-
duces vascular PGI2, which is a pivotal biologic
vasodilator and an inhibitor of platelet aggregation. Selec-
tive COX-2 inhibitors have no effect on TXA2 production
but, by decreasing PGI2 production, they may affect the
homeostatic balance between prothrombotic TXA2 and
antithrombotic PGI2, and may lead to an increase in throm-
botic cardiovascular events [20,21].
Given the results of several large clinical trials of COX-2
inhibitors, it is clear that the theoretical concern for a pro-
thrombotic effect is now transformed to a clinical reality.
The apparent hazard does not appear to be large and, in
absolute terms, may be a fraction of 1% excess and may
be confined to patients with an as yet undefined, specific
genetic susceptibility. With such an exceptionally large
patient population at risk, however, it is imperative to
determine the precise extent of the risk and the methods
to avoid risk. In patients with atherosclerotic heart disease,
the use of low-dose aspirin in conjunction with a COX-2
inhibitor is one possible way to mitigate the risk. However,
the data from the experimental celecoxib study performed
with aspirin [8] and the clinical trial allowing aspirin [14]
have failed to offer reassurance. Furthermore, the risk of
gastrointestinal bleeding is expected to be heightened
with concurrent use of aspirin and COX-2 inhibition such
that any clinical advantage over a NSAID could be lost.
The importance of the public health issue cannot be over-
stated. The class of drugs have yet to be assessed in a
single trial of patients with known atherosclerotic disease,
who stand to be at the highest risk of adverse events. The
population of patients taking COX-2 inhibitors includes
tens of millions of individuals with such concomitant
underlying disease. Ironically, the manufacturers of the
first-generation COX-2 inhibitors spent over $265 million
in 2001 for direct-to-consumer advertising to promote
their drugs [22], but have failed to conduct a prospective
trial of COX-2 inhibitors in patients with cardiovascular
disease. We will not have advanced in any meaningful way
in 2003 unless such a trial is undertaken.
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